Overview

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Status:
RECRUITING

Trial end date:
2029-05-29

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.

Phase:

PHASE4

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

belimumab